AI assistant
CANN GROUP LIMITED — Capital/Financing Update 2025
Apr 27, 2025
64603_rns_2025-04-27_9900cfbe-add3-41ab-a666-706c70dda958.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [114 x 53] intentionally omitted <==
ASX ANNOUNCEMENT
Cann Group Receives $836k Funding Advance on R&D Refund
28 April 2025 – Cann Group Limited (ASX: CAN) ( Cann or the Company ) announced today that it has entered into an agreement for an advance of $836,469 ( Advance ) from Radium Capital ( Radium ), providing early access to the Company’s expected Research and Development (R&D) Tax Incentive for FY2025, associated with R&D activities conducted up until the end of February 2025 ( R&D Refund ).
The Advance is to be provided under the terms of a loan agreement executed between Cann and Radium (the Loan Facility ). The Advance incurs an interest rate of 15.0% per annum, calculated daily which will be repaid on the date that proceeds of the R&D Refund are received, or 31 October 2025 (whichever occurs earlier).
Jenni Pilcher, CEO & Managing Director states: “The Advance will support Cann’s strategy of supplying the medicinal cannabis market with unique products developed through the R&D activities of the Company. This includes products sold under the Company’s Botanitech brand throughout Australia, including via the newly established collaboration with Chemist Warehouse outlets.”
Authorised for release by Steven Notaro, Company Secretary, Cann Group Limited.
For all other information please contact:
Jenni Pilcher Steven Notaro CEO & Managing Director Company Secretary Cann Group Limited Cann Group Limited +61 3 9095 7088 +61 3 9095 7088 [email protected] [email protected]
About Cann Group
Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology. Learn more at: www.canngrouplimited.com | www.satipharm.com
Cann Group Limited ACN 25 603 949 739, Australia 262-276 Lorimer Street, Port Melbourne 3207, Victoria, Australia Tel +61 (0) 3 9095 7088 | www.canngrouplimited.com